Spravato's Monotherapy Approval: A Game-Changer for TRD Treatment
Dr. Malina highlights Spravato's monotherapy approval as "groundbreaking for patients," simplifying TRD treatment and expanding its market. This breakthrough encourages further research by TRD drug developers, including psychedelics. Keta Medical Center has seen Spravato's transformative effects and is excited to offer this innovative option to more patients.